Heart failure in remission
Conditions
Brief summary
Left ventricular remodeling, measured in a core echocardiography laboratory as an increase in left ventricular end-systolic volume index of more than 20% from baseline, NT-proBNP increase to more than 500 pg/mL, All-cause mortality
Detailed description
Time to first occurrence of all-cause mortality or all-cause hospitalizations, Change in KCCQ-12, Proportion of patients requiring HF treatment re-initiation or escalation (i.e., (re-)initation of at least one guideline-directed medical therapy or starting a loop diuretic)
Interventions
DRUGLISINOPRIL EG 20 mg
DRUGcomprimé sécable
DRUGJardiance 10 mg film-coated tablets
DRUGBISOPROLOL EG 5 mg
DRUGSpironolactone 25mg Film-coated Tablets
Sponsors
Ziekenhuis Oost Limburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular remodeling, measured in a core echocardiography laboratory as an increase in left ventricular end-systolic volume index of more than 20% from baseline, NT-proBNP increase to more than 500 pg/mL, All-cause mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first occurrence of all-cause mortality or all-cause hospitalizations, Change in KCCQ-12, Proportion of patients requiring HF treatment re-initiation or escalation (i.e., (re-)initation of at least one guideline-directed medical therapy or starting a loop diuretic) | — |
Countries
Belgium
Outcome results
None listed